Brain Biomarker of Endogenous Analgesia in Patients With Chronic Knee Pain
1 other identifier
observational
110
1 country
1
Brief Summary
This case-control study in patients with knee osteoarthritis and pain-free control individuals aims to develop a brain biomarker of endogenous analgesia that may be used in subsequent clinical trials. Deficits in central nervous system (CNS) pain inhibition may contribute to chronic pain intensity, but quantitative sensory testing (QST) methods are limited. Incorporating brain imaging to assessments of CNS pain inhibition, by examining activity in relevant brain networks, would allow for an objective, physiologic measure of CNS pain inhibition. Preliminary data in pain-free volunteers implicate cortical activity measured with functional near-infrared spectroscopy (fNIRS) during CNS pain inhibition. Broadly, the investigators hypothesize that variability in CNS pain inhibition contributes to variability in clinical pain intensity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 6, 2021
CompletedFirst Posted
Study publicly available on registry
August 12, 2021
CompletedStudy Start
First participant enrolled
November 18, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 20, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
October 20, 2023
CompletedJanuary 13, 2025
January 1, 2025
1.9 years
August 6, 2021
January 9, 2025
Conditions
Outcome Measures
Primary Outcomes (4)
Differences in offset analgesia
Pain intensity difference during offset and control heat stimuli
15 minutes
Differences in brain region activation- QST
Difference in brain region activation (as measured by oxygenated hemoglobin, HbO) between CNS inhibition and control stimuli during QST procedures.
2-3 hours
Differences in brain region activation- walking test
Change in brain region activation (HbO) between rest and ambulation during the 6 minute walking test test
15 minutes
Differences in brain region activation- stair climbing
Change in brain region activation (HbO) between rest and ambulation during the stair climbing test
15 minutes
Secondary Outcomes (19)
Differences in resting fNIRS signaling
5-10 minutes
QST battery responses
2-3 hours
Pain intensity scores after stair climbing task
10 minutes
Pain intensity scores after walking test
6 minutes
Duration of stair climbing task
10 minutes
- +14 more secondary outcomes
Study Arms (3)
High Knee Pain with Osteoarthritis
Adults 45-80 years old who have moderately severe knee osteoarthritis and rate their daily knee pain at \>=6 on a 0-10 numeric rating scale
Low Knee Pain with Osteoarthritis
Adults 45-80 who have moderately severe knee osteoarthritis and rate their daily knee pain at \<=5 on a 0-10 numeric rating scale
Healthy Controls
Age matched, BMI matched adults who do not have knee osteoarthritis or chronic pain
Eligibility Criteria
Participants will be recruited from the Pitt+Me registry which comprises of any members of the local population who are registered in the program.
You may qualify if:
- For the knee arthritis groups: Chronic knee pain with evidence of knee osteoarthritis - radiographically grades 2-4
- Age: 45-80 years old
- Gender: Males and females will be recruited.
- Language: only English-speaking subjects will be included.
You may not qualify if:
- Inflammatory arthritis (e.g. rheumatoid arthritis)
- Inability to walk and climb stairs unassisted
- History of knee replacement or open knee surgery
- History of arthroscopic knee surgery within the last 3 months (\>3 months does not exclude participant)
- History of knee radiofrequency nerve ablation or ligation
- Current opioid use
- Current use of antidepressants that are not in the serotonin-selective reuptake inhibitor (SSRI) class. Patients who are currently using an SSRI are allowed to take part in the study
- Cognitive impairment affecting the ability to provide informed consent, understand directions, and participate in study procedures
- Uncontrolled or unstable medical disorder preventing participation in study procedures
- History of brain surgery
- Tattoos on forearm or knee
- Pregnancy
- Patients with chronic pain conditions that are more severe than their knee arthritis pain (e.g., CRPS, fibromyalgia)
- Patients whose most painful knee is excluded for another reason (e.g., recent surgery on most painful knee)
- For the pain-free control group: a history of chronic pain
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UPMC Pain Medicine at Centre Commons
Pittsburgh, Pennsylvania, 15206, United States
Related Publications (1)
Alter BJ, Maurer M, O'Connell B, Sanchez AG, Kaynar AM, DiGioia AM, Huppert T, Wasan AD. Deficits in temporal pain inhibition are associated with greater pain and functional impairment in osteoarthritis. Pain. 2025 Nov 1;166(11):2490-2509. doi: 10.1097/j.pain.0000000000003648. Epub 2025 Jun 19.
PMID: 40539481DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Benedict Alter, MD, PhD
University of Pittsburgh
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
August 6, 2021
First Posted
August 12, 2021
Study Start
November 18, 2021
Primary Completion
October 20, 2023
Study Completion
October 20, 2023
Last Updated
January 13, 2025
Record last verified: 2025-01
Data Sharing
- IPD Sharing
- Will not share